secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K
Filed at:   2025-07-10T23:59:59+00:00
Accession:  0000950170-25-094921
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud

Mereo BioPharma and Ultragenyx Provide Update on Phase 3 Orbit and Cosmic Studies of UX143 in Osteogenesis Imperfecta
--------------------------------------------------------------------------------

- The Phase 3 Orbit study final analysis is expected around end of 2025, with a threshold of p<0.04.
- DMC informed Ultragenyx that UX143 has an acceptable safety profile and study should continue to final analysis.
- Safety in the younger patient population (Cosmic study) is consistent with other studies; no interim analysis of Cosmic data.
- Final analyses will occur after patients have been on therapy for at least 18 months; threshold for Cosmic is p<0.05.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000095017025094921/0000950170-25-094921-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000095017025094921/mreo-20250709.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-094921

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer